Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

AstraZeneca
McKinsey
Dow
Boehringer Ingelheim
Merck
McKesson

Last Updated: October 19, 2019

DrugPatentWatch Database Preview

Trastuzumab - Biologic Drug Details

See Plans and Pricing

« Back to Dashboard

Summary for trastuzumab
Tradenames:1
Patents:852
Applicants:1
BLAs:1
Suppliers: see list1
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for trastuzumab
Pharmacology for trastuzumab
Mechanism of ActionHER2/Neu/cerbB2 Antagonists

US Patents for trastuzumab

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech HERCEPTIN trastuzumab VIAL; INTRAVENOUS 103792 001 1998-09-25   Start Trial Novartis AG (Basel, CH) 2038-10-10 RX Orphan search
Genentech HERCEPTIN trastuzumab VIAL; INTRAVENOUS 103792 001 1998-09-25   Start Trial Array BioPharma Inc. (Boulder, CO) 2029-10-21 RX Orphan search
Genentech HERCEPTIN trastuzumab VIAL; INTRAVENOUS 103792 001 1998-09-25   Start Trial ACADEMIA SINICA (Taipei, TW) 2034-05-27 RX Orphan search
Genentech HERCEPTIN trastuzumab VIAL; INTRAVENOUS 103792 001 1998-09-25   Start Trial XUANZHU PHARMA CO., LTD. (Jinan, Shandong Province, CN) 2034-09-29 RX Orphan search
Genentech HERCEPTIN trastuzumab VIAL; INTRAVENOUS 103792 001 1998-09-25   Start Trial Yeda Research and Development Co. Ltd. (Rehovot, IL) 2034-09-08 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Supplementary Protection Certificates for trastuzumab

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1689846/01 Switzerland   Start Trial PRODUCT NAME: TRASTUZUMAB ENTANSINE; REGISTRATION NO/DATE: SWISSMEDIC 62892 02.05.2013
2013028,C1689846 Lithuania   Start Trial PRODUCT NAME: TRASTUZUMABUM EMTANSINUM; REGISTRATION NO/DATE: EU/1/13/885 20131119
0150014 00145 Estonia   Start Trial PRODUCT NAME: IBRUTINIIB;REG NO/DATE: EU/1/14/945 23.10.2014
/2013 Austria   Start Trial PRODUCT NAME: TRASTUZUMAB EMTANSIN; REGISTRATION NO/DATE: EU/1/13/885 20131119
2015 00006 Denmark   Start Trial PRODUCT NAME: POMALIDOMID OG FARMACEUTISK ACCEPTABLE SALTE, SOLVATER, HYDRATER ELLER STEREOISOMERER HERAF; REG. NO/DATE: EU/1/13/850 20130805
>Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Harvard Business School
McKesson
Express Scripts
Baxter
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.